Homepage Top Section2

The funds will help YolTech in advancing its clinical programmes and global strategic execution. Established in 2021, YolTech Therapeutics is stated to be advancing next-generation in vivo gene-editing

The company aims to achieve early clinical proof-of-concept for the therapy by late 2026. Dewpoint noted that the financing will also expedite the development of its first-in-class c-mod

AS, a rare neurological disorder often diagnosed in infancy, affects approximately one in 21,000 individuals worldwide and is caused by the loss of function of the maternal UBE3A

The gut microbiome is composed of microorganisms, including viruses, bacteria, and fungi, that naturally reside in the human gut. The companies will work together to investigate solutions aimed

VWD is the most prevalent inherited bleeding disorder in the US, affecting over three million individuals, with both men and women equally susceptible. Vonvendi is also approved for

This designation applies when olomorasib is used in combination with the anti-PD-1 therapy Keytruda (pembrolizumab) for the initial treatment of unresectable advanced or metastatic non-small cell lung cancer

According to the agreements, MS Pharma will oversee the registration, marketing along with the distribution of vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019) throughout MENA. Polpharma Biologics will

This round of financing was led by SV Health Investors’ Dementia Discovery Fund (DDF), with contributions from existing investors including Newpath Partners, OrbiMed, Euclidean Capital, Chugai Venture Fund,

This change eliminates the previous requirement for a cardiovascular disease diagnosis prior to treatment. Amgen global commercial operations executive vice president Murdo Gordon said: “Far too many adults